AlloVir, Inc. (NASDAQ:ALVR – Get Free Report)’s share price traded down 2.4% during trading on Thursday. The company traded as low as $1.95 and last traded at $2.02. Approximately 84,364 shares traded hands during mid-day trading, an increase of 438% from the average session volume of 15,685 shares. The stock had previously closed at $2.07.
AlloVir Stock Performance
The stock has a 50-day moving average price of $3.24 and a two-hundred day moving average price of $4.26. The stock has a market capitalization of $10.19 million, a PE ratio of -0.10 and a beta of 0.63.
AlloVir Company Profile
AlloVir, Inc was a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, virus-specific T-cell therapies for patients whose immune systems are compromised and who are unable to effectively fight viral infections. Its approach was designed to restore or enhance antiviral immunity without requiring the patient to generate an effective immune response independently.
The company’s pipeline included posoleucel, also known as ALVR105, an investigational multi-virus-specific T-cell therapy targeting infections caused by adenovirus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, BK virus and JC virus.
Further Reading
- Five stocks we like better than AlloVir
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
